This piece really resonates with me, in particular "far less attention is devoted to sustaining the human ecosystem that generates the biological knowledge AI ultimately depends upon." Investment in people generating/curating the knowledge AI is trained upon/uses is required in parallel.

Cancer Research UK City of London Centre@cruk-cityoflondon.bsky.social · 3w ago

It's a timely reminder that breakthroughs depend not only on powerful technologies, but also on the research cultures that bring together diverse expertise, foster creativity and create opportunities for unexpected discoveries. Read the commentary: www.nature.com/artic... 3/3

New NLCA publication: Curative-Intent Radiotherapy in the Era of Earlier Lung Cancer Diagnosis: Insights from the National Lung Cancer Audit Read the article here 👉 www.natcan.org.uk/library/the-... @hqip.bsky.social @btog.bsky.social @lcnuk.bsky.social @natcan-news.bsky.social

📢 Two new Cancer Grand Challenges 📢 Applications close 24 November. Discover the new challenges: bit.ly/4xfm78b Winning teams will be funded by the Torrey Coast Foundation and Cancer Research UK (CRUK), through Cancer Grand Challenges.

1/ NEW PAPER 🎉 🧵 We mapped the mutational processes shaping 959 prostate cancer genomes from the Pan Prostate Cancer Group (PPCG), integrating SBS, ID, CX and complex SV signatures. Eight footprints account for the processes in 85% of cases www.nature.com/articles/s41... @nature.com

Integrated signatures define mutational processes in prostate cancer - Nature

Eight integrated mutational footprints collectively explain the mutational processes in 85% of primary prostate cancer genomes.

nature.com

The latest results from the Pan Prostate Cancer Group identify eight integrated mutational footprints in primary prostate cancer. A phenomenal amount of work and data. Another step towards further understanding what drives prostate cancer. www.nature.com/articles/s41...

Have a spare 5 minutes? 💬 We're gathering feedback to help improve the Cancer Grand Challenges website and would love to hear your thoughts. Complete our short survey: ows.io/tj/d10fadb3

Welcome | by Optimal Workshop

ows.io

Huge congratulations to Becki and team. I remember when this was developing as a proposed study and it is brilliant to see its conclusion. Becki is so persistent in her drive to improve care for people with melanoma, really proud to see this out.

Becki Lee@beckilee.bsky.social · 5mo ago

Pleased to share results from the CAcTUS Phase II trial of ctDNA-guided therapy in BRAF-mutant advanced melanoma are now published! 🌵🧬 CAcTUS is the first melanoma trial to adapt treatment based on ctDNA testing. Read: www.nature.com/articles/s41...

📢 New job alert! I've started as Programme Manager for www.cancergrandchallenges.org/rewire-can @cancergrand.bsky.social @ucl.ac.uk with Bart Vanhaesebroeck & @christophertape.bsky.social. Really excited about this new chapter. I had a fantastic time with @natcan-news.bsky.social & will miss it.

new out in Nature: www.nature.com/articles/s41...

Evolutionary characterization of lung cancer metastasis - Nature

DNA-sequencing data from primary tumours and paired metastases from participants in the TRACERx lung study and PEACE autopsy programme are used to analyse the metastatic diversity of advanced non-smal...

nature.com

Couldn't agree more. This is horrifying. Appreciate there aren't easy solutions but vast improvements are needed.

Pippa Crerar@pippacrerar.bsky.social · 6mo ago

‘It’s soul-destroying’: struggle to house vulnerable children can leave breaking law as only option - such important reporting from @lexytopping.bsky.social www.theguardian.com/society/2026...

It's a big Quality Improvement day for my audits today. At 9am, @npca-natcan.bsky.social is hosting a webinar www.natcan.org.uk/events/webin... as part of our QI intervention www.natcan.org.uk/quality-impr.... It will be recorded so you can watch back. And today in the @nkca-natcan.bsky.social...

This is absolutely brilliant. Instigated by Gordon Brown, delivered today. www.bbc.co.uk/news/article...

World's longest coastal path opens in England to the public

The King Charles coastal path will allow walkers right of access to the entire coast for the first time.

bbc.co.uk

It's #NationalCancerCNSDay! NKCA is working to improve access to CNS support through a new Quality Improvement intervention. 💡Find more on our website: buff.ly/3xcrp8P 📊Check your trust’s data on our data dashboard: buff.ly/jDx7KjX @ukons.bsky.social @baunnurses.bsky.social

Congratulations to Arjun for this important paper. Read, share and follow @npca-natcan.bsky.social for news/papers from the National Prostate Cancer Audit, plenty more to come!

National Prostate Cancer Audit@npca-natcan.bsky.social · 8mo ago

📝 OUT NOW! NPCA Clinical Fellow, Arjun Nathan, published a paper on characteristics and outcomes of men presenting with complications of metastatic prostate cancer in BJUI. View full paper 👉 buff.ly/QJ3Eew1

OpenSAFELY is open from today! Huge thanks to all who supported this vast collaboration: whole population GP data; in a productive platform; innovative privacy protections; unprecedented support from professions, privacy campaigners; &c Now it's over to users! www.bennett.ox.ac.uk/blog/2026/02...

OpenSAFELY news: you can apply to do non-COVID research, from today! | Bennett Institute for Applied Data Science

We are delighted to announce that - from today - you can submit applications to the OpenSAFELY service for non-COVID-19 studies.

bennett.ox.ac.uk

Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine In this Review, Alice Bernard-Tessier & @mishabeltran.bsky.social discuss the underlying biology in mHSPC and highlight current knowledge gaps: doi.org/10.1172/JCI2...

Very clear thread, well worth reading and sharing.

Philip Ball@philipcball.bsky.social · 9mo ago

I had intended to post something about this new Google DeepMind paper that appeared yesterday in Nature, but the press coverage has added to what there is to say. So this is a long 🧵 www.nature.com/articles/s41...

Exciting conference alert! sites.manchester.ac.uk/from-lab-to-... Fantastic speakers including Chris Marine, Christian Blank Melanoma evolution Local microenvironment of melanoma Melanoma-host interactions Precision immunotherapy Emerging therapeutics Clinical trials and real-world data

🔔3 Days to Go! Join Us for the NATCAN Webinar at @londonglobalcancer.bsky.social 📅 Thursday, 27 November 🕙 10:30 AM – 12:00 PM (GMT) Last chance to register: natcan.org.uk/events/londo... #LGCW2025 #LondonGlobalCancerWeek

Fantastic opportunity from @turajliclab.bsky.social! 🚀 The CanDy Lab is recruiting an Associate Scientist to drive cutting-edge cancer research across @cruk-mi.bsky.social and @crick.ac.uk. A rare chance to lead, grow, and shape high-impact science 👇 www.cruk.manchester.ac.uk/career/mi-25...

MI/25/63 Associate Scientist | Cancer Research UK Manchester Institute

We are seeking a highly motivated and accomplished Associate Scientist to help lead and shape the programme. You will act as an operational deputy to Professor Samra Turajlic, helping to bridge activi...

cruk.manchester.ac.uk

So proud of my colleague Sacha Howell on this latest @nature.com publication reporting on the Breast Cancer-Anti-Progestin Prevention Study 1 (BC-APPS1) - many years in the making: www.nature.com/articles/s41... Press release from The University of Manchester: www.manchester.ac.uk/about/news/n...

New study uncovers potential way to prevent breast cancer in pre-menopausal women

A University of Manchester study funded by Breast Cancer Now and supported by Prevent Breast Cancer, reveals a drug approved for use in other conditions could be repurposed to prevent breast cancer in...

manchester.ac.uk

The UK’s first one-stop kidney cancer clinic at @cuh.nhs.uk is transforming kidney cancer diagnosis. With a confocal microscope, patients can get a biopsy, diagnosis & treatment plan – all on the same day. Find out more: crukcambridgecentre.org.uk/news/one-sto... @crukcamurol.bsky.social

New CMO report out today on health trends and variation in England. My team delivered this using a RAP developed in R, which made a nice change from lots of people running around putting numbers into excel then pasting into powerpoint... Was not without challenges though! www.gov.uk/government/p...

Health trends and variation in England 2025: a Chief Medical Officer report

An overview of the health of England’s population, including trends over time and geographical variation.

gov.uk

1/2 With #WorldCancerResearchDay shining a light on cancer care, we update on the HQIP-commissioned National Cancer Audit Collaborating Centre, which hosts all ten #NHS national cancer audits that are part of the National Clinical Audit and Patient Outcomes Programme. @natcan-news.bsky.social

Our new website is live! 🎉 All 10 national cancer audits are now in one place: bowel, OG, NHL, lung, ovarian, kidney, prostate, pancreatic, primary breast & metastatic breast. Plus refreshed QI & new sections have been added, check it out here 👉 natcan.org.uk

ICYMI and want to know more about how tumor transcription-wide expression classifiers predict treatment sensitivity in advanced prostate cancers > look no further: www.cell.com/cell/pdf/S00...

Marina Parry@marinaparry.bsky.social · last yr.

REALLY thrilled to share findings from my postdoc work in the Attard lab, which form part of this www.sciencedirect.com/science/arti.... Thanks to Emily and Gert for seeing it over the line, all the funders, the Veracyte, MRC CTU & STAMPEDE teams, and patients who contributed samples. Pls share!

Could transcriptome signatures identify men with advanced #ProstateCancer most likely to benefit from chemotherapy? A brilliant team led by Prof Gerhardt Attard @ucl.ac.uk share exciting new findings in @cp-cell.bsky.social. Grab a ☕ and read: doi.org/10.1016/j.ce...

A new test can identify which prostate cancer patients are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit from unpleasant side effects, shows a new study led by Prof Gert Attard & Dr Emily Grist @uclmedsci.bsky.social www.ucl.ac.uk/news/2025/au...

Molecular test personalises prostate cancer treatment

Testing the molecular profile of tumours identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit f...

ucl.ac.uk

REALLY thrilled to share findings from my postdoc work in the Attard lab, which form part of this www.sciencedirect.com/science/arti.... Thanks to Emily and Gert for seeing it over the line, all the funders, the Veracyte, MRC CTU & STAMPEDE teams, and patients who contributed samples. Pls share!

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

Advanced prostate cancers respond to hormone therapy but outcomes vary and no predictive tests exist for informed treatment selection. To identify nov…

sciencedirect.com

📢 Start your week with the latest National Prostate Cancer Audit study. We found that the annual rate of metastatic prostate cancer at diagnosis was more than 60% higher in some regions than in others in England. Paper link here 👉 bmjoncology.bmj.com/content/4/1/...

Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation

Objective To evaluate the area-based incidence of metastatic prostate cancer at diagnosis, reflecting the risk of late-stage diagnosis, and overall prostate cancer incidence, reflecting the risk of ov...

bmjoncology.bmj.com